Isotechnika Inc. Invited To Present At Rodman & Renshaw Annual Healthcare Conference

EDMONTON, AB, Nov. 3 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that Dr. Randall Yatscoff, President & CEO of Isotechnika will present a corporate and scientific update at the 7th Annual Rodman & Renshaw Healthcare Conference. The conference will take place November 7-9, 2005 at the Palace Hotel in New York City. Dr. Yatscoff's presentation is scheduled for Monday, November 7th at 9:45 a.m. ET in the Kennedy I room.

All interested parties are encouraged to visit http://wsw.com/webcast/rrshq7/isa/ to listen to a live Web cast of Dr. Yatscoff's presentation. Dr. Yatscoff's presentation will also be made available through the investor relations section of our corporate Web site at www.isotechnika.com.

In addition to the Rodman & Renshaw Healthcare conference, Dr. Yatscoff will also be providing an update to attendees of the CIBC World Markets' 16th Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on November 8th at 2:30 p.m. ET.

About Isotechnika -----------------

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis. In addition, ISA247 has successfully completed a Phase IIa trial for kidney transplantation. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which is in Phase I.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

CONTACT: Dr. Randall Yatscoff, President & CEO, Isotechnika Inc., (780)487-1600 (246), (780) 484-4105 (fax), ryatscoff@isotechnika.com; StephanieGillis-Paulgaard, Senior Manager, Corporate Communications, IsotechnikaInc., (780) 487-1600 (243), (780) 484-4105 (fax),sgillis-paulgaard@isotechnika.com; Archived images on this organization aresearchable through CNW Photo Archive website at http://photos.newswire.ca.Images are free to accredited members of the media. To request a free copyof this organization's annual report, please go to http://www.newswire.caand click on Tools for Investors.